VZV IgG and IgG avidity ELISA Kit (DEIA473)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Species Reactivity
Intended Use
VZV IgG and IgG avidity ELISA Kit is intended for in vitro diagnosis of VZV associated diseases, namely varicella and herpes zoster. The diagnostic kit can also beutilized for differential diagnosis of neuro infections, infections of eye and skin exanthematous diseases.
Contents of Kit
1. ELISA break-away strips (blue)
2. positive control serum
3. Positive control serum
4. Negative control serum
5. Anti-human IgG antibodies
6. Wash buffer
7. Dilution buffer (DB)
8. Urea solution
9. Chromogenic substrate (TMB substrate)
10. Stop solution
Store the kit reagents at 2-8°C. For longer period make aliquots and keep them at -20°C. Avoid repeated thawing and freezing. For more detailed information, please download the following document on our website
Intraassay variability: 2.6-6.6%
Interassay variability: 24-41% (RAI%: 34 ± 4.8); 77-95% (RAI%: 87 ± 5.8)


Have you cited DEIA473 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Successful management of visceral disseminated varicella zoster virus infection during treatment of membranous nephropathy: a case report


Authors: Furuto, Yoshitaka; Kawamura, Mariko; Namikawa, Akio; Takahashi, Hiroko; Shibuya, Yuko

Background: Visceral disseminated varicella zoster virus (VDVZV) infection is a rare disease with a high mortality rate (55%) in immunocompromised patients, but it is not yet widely recognized in the field of nephrology. We report a case of VDVZV contracted during immunosuppressive therapy for membranous nephropathy. Case presentation: A 36-year-old woman was diagnosed with membranous nephropathy and was being treated with immunosuppressive therapy consisting of 60 mg/day prednisolone, 150 mg/day mizoribine, and 150 mg/day cyclosporine. Nephrosis eased; therefore, the prednisolone dosage was reduced. However, 50 days after starting immunosuppressive therapy, the patient suddenly developed strong and spontaneous abdominal pain, predominantly in the epigastric area, without muscular guarding or rebound tenderness. Blood data indicated neutrophil-dominant elevated white blood cell count, reduced platelet count, elevated transaminase and lactate dehydrogenase, slightly increased C-reactive protein, and enhanced coagulability. Abdominal computed tomography revealed a mildly increased enhancement around the root of the superior mesenteric artery with no perforation, intestinal obstruction, or thrombosis. The cause of the abdominal pain was unknown, so the patient was carefully monitored and antibiotic agents and opioid analgesics administered. The following day, blisters appeared on the patient's skin, which were diagnosed as varicella. There was a marked increase in the blood concentration of VZV-DNA; therefore, the cause of the abdominal pain was diagnosed as VDVZV. Treatment with acyclovir and immunoglobulin was immediately started, and the immunosuppressive therapy dose reduced. The abdominal pain resolved rapidly, and the patient was discharged 1 week after symptom onset. Discussions and conclusions: This patient was VZV-IgG positive, but developed VDVZV due to reinfection. Abdominal pain due to VDVZV precedes the skin rash, which makes it difficult to diagnose before the appearance of the rash, but measuring the VZV-DNA concentration in the blood may be effective. Saving the patient's life requires urgent administration of sufficient doses of acyclovir and reduced immunosuppressive therapy.

Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women


Authors: Perciani, Catia T.; Sekhon, Manmeet; Hundal, Sabrina; Farah, Bashir; Ostrowski, Mario A.; Anzala, A. Omu; McKinnon, Lyle R.; Jaoko, Walter; MacDonald, Kelly S.

Background. Attenuated varicella zoster virus (VZV) is a promising vector for recombinant vaccines. Because human immuno-deficiencyvirus (HIV) vaccines are believed to require mucosal immunogenicity, we characterized mucosal VZV-specific humoral immunity following VZV(Oka) vaccination. Methods. Adult Kenyan VZV-seropositive women (n = 44) received a single dose of the live zoster VZVOka vaccine. The anamnestic responses to the virus were followed longitudinally in both plasma and mucosal secretions using an in-house glycoprotein enzyme-linked immunosorbent assay and safety and reactogenicity monitored. VZV seroprevalence and baseline responses to the virus were also characterized in our cohorts (n = 288). Results. Besides boosting anti-VZV antibody responses systemically, vaccination also boosted anti-VZV immunity in the cervicovaginal mucosa with a 2.9-fold rise in immunoglobulin G (P <.0001) and 1.6-fold rise in immunoglobulin A (IgA) (P =.004) from the time before immunization and 4 weeks postvaccination. Baseline analysis demonstrated high avidity antibodies at the gastrointestinal and genital mucosa of VZV-seropositive women. Measurement of VZV-specific IgA in saliva is a sensitive tool for detecting prior VZV infection. Conclusions. VZV(Oka) vaccine was safe and immunogenic in VZV-seropositive adult Kenyan women. We provided compelling evidence of VZV ability to induce genital mucosa immunity.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket